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Mutations in the type VII collagen gene, COL7A1,
give rise to the blistering skin disease, dystrophic
epidermolysis bullosa. We have developed two new
mutation detection strategies for the screening of
COL7A1 mutations in patients with dystrophic
epidermolysis bullosa and compared them with an
established protocol using conformational sensitive gel
electrophoresis. The first strategy consisted of an RNA
based protein truncation test that amplified the entire
coding region in only four overlapping nested reverse
transcriptase-polymerase chain reaction assays. These
fragments were transcribed and translated in vitro and
analyzed using sodium dodecyl sulfate-polyacrylamide
gel electrophoresis. We have used the protein trunc-
ation test procedure to characterize 15 truncating
mutations in 13 patients with severe recessive dys-
trophic epidermolysis bullosa yielding a detection sen-
sitivity of 58%. The second strategy was a DNA-based
fluorescent chemical cleavage of mismatch (fl-CCM)
procedure that amplified the COL7A1 gene in 21
Dystrophic forms of epidermolysis bullosa (DEB)encompass a group of autosomal disorders character-ized by fragility of the skin and mucous membranes.Ultrastructurally, skin from DEB patients showsmorphologic abnormalities in anchoring fibrils at
the dermal–epidermal junction (Tidman and Eady 1985), which
are composed of type VII collagen (Burgeson, 1993). The molecular
pathology of both autosomal dominant and recessive forms of DEB
results from mutations in the type VII collagen gene, COL7A1
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polymerase chain reaction assays. Mismatches, formed
between patient and control DNA, were identified
using chemical modification and cleavage of the DNA.
We have compared fl-CCM with conformational sen-
sitive gel electrophoresis by screening a total of 50
dominant and recessive dystrophic epidermolysis bul-
losa patients. The detection sensitivity for fl-CCM was
81% compared with 75% for conformational sensitive
gel electrophoresis (p 5 0.37 c2-test). Using a combin-
ation of the three techniques we have screened 93
dystrophic epidermolysis bullosa patients yielding an
overall sensitivity of 87%, detecting 79 different
mutations, 57 of which have not been reported pre-
viously. Comparing all three approaches, we believe
that no single method is consistently better than the
others, but that the fl-CCM procedure is a sensitive,
semiautomated, high throughput system that can be
recommended for COL7A1 mutation detection. Key
words: epidermolysis bullosa/skin blistering. J Invest
Dermatol 113:673–686, 1999
(Ryynanen et al, 1991, 1992; Hovnanian et al, 1992) (GenBank
no. L23982). The gene spans approximately 32 kb of 3p21.1 and
consists of 118 coding exons (Christiano et al, 1994a). The COL7A1
transcript is 9.2 kb (Christiano et al, 1994b) of which 8.8 kb codes
for a pro-α chain of 2944 amino acids with a molecular mass of
320 kDa. Type VII collagen molecules consist of a central colla-
genous domain consisting of gly X-Y repeats, and noncollagenous
domains at the amino (NC-1) and carboxyl (NC-2) ends. In vivo,
three pro-α molecules form homotrimers [(α1(VII)], which then
form antiparallel dimers and aggregate laterally to form anchoring
fibrils (Burgeson, 1993). Analysis of COL7A1 mutations in patients
with different forms of DEB has established some genotype-
phenotype correlations (Jarvikallio et al, 1997). For example, most
cases of dominant DEB are caused by missense mutations within
the collagenous domain and consist mainly of glycine substitutions
that cause destabilization of the gly X-Y repeats necessary for the
integrity of the triple helix. Anchoring fibrils may appear normal
but are often reduced in number. With a few exceptions, the
severe autosomal recessive forms of DEB are caused by truncating
mutations (i.e., nonsense, frame-shift, and splice-site mutations) on
both alleles in either a homozygous or more commonly a compound
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heterozygous state. These mutations should lead to type VII
collagen molecules lacking certain domains that are necessary for
anchoring fibril formation; however, before translation can occur
in vivo, the majority of the transcripts are degraded via nonsense
mediated mRNA decay (Christiano et al, 1997b) and hence no
anchoring fibrils are formed. The intermediate forms of recessive
DEB are caused by a range of different types of COL7A1 mutations,
including a truncating mutation on one allele and a missense
mutation on the other allele, splice site mutations, or a delayed
termination codon. In addition, not all glycine substitutions result
in dominant negative interference: some may be inherited reces-
sively and only contribute to a DEB phenotype when inherited in
trans with a COL7A1 mutation on the other allele (Christiano et al,
1996d). Anchoring fibrils in these intermediate forms of recessive
DEB are usually thin, more wisp-like, and reduced in number
(McGrath et al, 1993; Bruckner-Tuderman et al, 1995; Dunnill
et al, 1996).
To date, all COL7A1 mutations described consist either of base
substitutions or of small insertions/deletions of less than 30 bp,
hence the design of a mutation detection strategy can be based on
the detection of these small sequence changes. There are many
mutation detection techniques available to scan for sequence
changes in cellular RNA or genomic DNA, and these include
denaturing gradient gel electrophoresis (DGGE) (Myers et al, 1987),
chemical cleavage of mismatch (CCM) (Cotton et al, 1988), single
stranded conformation polymorphism (SSCP) (Orita et al, 1989),
heteroduplex analysis (HA) (White et al, 1992), conformation
sensitive gel electrophoresis (CSGE) (Ganguly et al, 1993), and the
protein truncation test (PTT) (Roest et al, 1993a). The most critical
factor that determines the success of any gene screening protocol
is the sensitivity of the detection technique. In addition, when
choosing a mutation screening strategy using genomic DNA, the
size of the gene and its number of exons must be taken into
account. The sensitivities of these methods vary greatly depending
on the size of template screened. For example SSCP has a sensitivity
of .95% for fragments of 155 bp but this is reduced to only 3%
for 600 bp (Sheffield et al, 1993). Once optimized, DGGE has a
sensitivity of ~99% for fragments of up to 500 bp (Fodde and
Losekoot, 1994), and CSGE is expected to have a sensitivity of
80%–90% for fragments of up to 600 bp. CCM on the other hand
has a sensitivity of 95%–100% for fragments . 1.5 kb in size
(Rowley et al, 1995) and is ideal for screening compact genes
where more than one exon can be amplified together using
genomic DNA as the template. All these techniques detect sequence
changes such as truncating and missense mutations as well as
polymorphisms; however, the PTT screens only for truncating
mutations and is predicted to have a sensitivity of . 95% and can
be used for RNA or DNA fragments in excess of 3 kb.
COL7A1 mutation screening studies to date have used either
DNA or RNA as the template and have used detection techniques
such as SSCP (Christiano et al, 1993; Dunnill et al, 1996), direct
sequencing (Gardella et al, 1996; Winberg et al, 1997), DGGE
(Hilal et al, 1993; Hovnanian et al, 1994), HA (Christiano et al,
1996a), or CSGE (Christiano et al, 1996b; Hammami-Hauasli et al,
1997; Kon et al, 1997a, b; Mellerio et al, 1997), with the latter
being the most popular due to its ease of use. Recently, a protocol
has been published (Christiano et al, 1997a) to permit screening of
the entire COL7A1 coding region and its splice sites via the
amplification of all 118 exons from genomic DNA using 72 separate
polymerase chain reaction (PCR) assays ranging in size from 196 bp
to 589 bp. These amplification products are then screened for
sequence changes using CSGE. We have implemented this strategy,
but have investigated alternative screening strategies to reduce the
workload and to increase the overall mutation detection efficiency.
We have therefore developed two new mutation detection
techniques for screening COL7A1, which are easier to use, less
labor intensive, and cheaper than the CSGE protocol. Firstly, we
have developed an RNA based PTT as a high throughput screen
for use solely for screening patients with severe, generalized recessive
DEB, in whom the COL7A1 mutations would be expected to
comprise truncating mutations on both alleles. The protocol
amplifies the entire open reading frame of COL7A1 in only four
overlapping nested reverse transcriptase (RT)-PCR assays of 2.6 kb
in size using blood lymphocyte total RNA as the template. These
RT-PCR fragments are transcribed and translated in vitro using a
coupled T7 rabbit reticulocyte lysate system and analyzed using
SDS-PAGE. Secondly, we have developed a technique for screening
all DEB patients. This is based on the amplification of 21 separate
genomic DNA fragments of between 620 bp and 1604 bp encom-
passing all exons, splice sites, and . 80% of introns of the COL7A1
gene. Sequence changes are detected using solid-phase fluorescent
chemical cleavage of mismatch (fl-CCM) (Rowley et al, 1995).
Chemical cleavage of mismatch (Cotton et al, 1988) is based upon
the chemical reactivity of mismatched bases such as cytosine when
it is mismatched with itself, adenine, or thymine, or when thymine
is mismatched with itself, cytosine, or guanine.
We present comparative data for the new strategies assessed
alongside the already standardized CSGE procedure and also provide
a summary of all of the mutation data collected for all strategies
over the past 3 y.
MATERIALS AND METHODS
RT-PCR PTT strategy Following informed consent, total RNA was
extracted from 2 to 10 ml peripheral blood using a standard acid guanidinium
thiocyanate-phenol-chloroform method (Chomczynski and Sacchi, 1987).
Primers used for the reverse transcriptions (COLxB) and the first (COLxA
and COLxB) and second (COLxC-T7 and COLxD) rounds of amplification
are presented in Table I. Reverse transcription was performed by adding
200–500 ng of total RNA to 10 ng of primer COLxB (where x 5 1–4)
in a total volume of 4 µl and overlaid with 50 µl of mineral oil. Reactions
were incubated at 65°C for 10 min before being snap-chilled on ice. Six
microliters of an RT premix containing RT buffer, 10 nmol of each dNTP,
200 units of M-MLV RT (Promega, Madison, WI), and 40 units of RNasin
ribonuclease inhibitor (Promega) was added to the samples and incubated
at 42°C for 1 h followed by 95°C for 3 min. The RT reaction was added
to a primary PCR premix containing PCR buffer (60 mM KCl, 20 mM
Tris-HCl pH 8.8, 1.5 mM MgCl2, 8% glycerol), 20 pmol of each primer
COLxA and COLxB (where x 5 1–4) to yield a final volume of 50 µl.
After an initial denaturation of 94°C for 2 min, 2.5 units of Taq Plus Long
(Stratagene, La Jolla, CA) was added, followed by 30 cycles of 94°C for
10 s, 65°C for 30 s, and 72°C for 2.5 min with a final incubation of 72°C
for 5 min. Two microliters of the primary PCR was added to a secondary
PCR premix containing PCR buffer (60 mM KCl, 20 mM Tris-HCl
pH 8.8, 1.5 mM MgCl2, 8% glycerol), 10 nmol of each dNTP, and
20 pmol of each primer COLxC and COLxD (where x 5 1–4) to yield
a final volume of 50 µl. After an initial denaturation of 94°C for 2 min,
2.5 units of Taq Plus Long (Stratagene) were added and cycling was
performed as for the primary PCR. Five microliters of the secondary PCR
product was electrophoresed in a 1% agarose minigel containing ethidium
bromide. Unpurified PCR products (3.6 µl) were transcribed and translated
in vitro at 30°C for 90 min using a T7 coupled rabbit reticulocyte lysate
system (Promega) as per the manufacturer’s instructions using a total
volume of 12.5 µl with the addition of 1.5 mM MgCl2 to reduce
nonspecific translation products (Whittock et al, 1997). Translation products
were electrophoresed through a 5%/10% discontinuous SDS-PAGE gel
with Tris-glycine buffer on a 20 cm 3 20 cm 3 1 mm vertical gel
apparatus (Flowgen, U.K.) at 10 V per cm for 3 h (Fig 1). High range
14C Rainbow markers (Amersham, U.K.) were used. The gel was fixed
in 7% acetic acid for 30 min followed by soaking in Amplify (Amersham)
for 30 min. The gel was dried under vacuum at 60°C for 30 min followed
by 80°C for 60 min. The signal was detected by autoradiography on
standard X-ray film. Once a protein truncating mutation was suspected by
observation of an aberrant protein band, the nature of the mutation was
determined by sequencing the relevant secondary RT-PCR product, and
then confirmed by sequencing the specific exon of COL7A1 using the
patient’s genomic DNA as the template. Amplification from genomic DNA
was performed using approximately 100 ng of genomic DNA added to a
premix containing PCR buffer [67 mM Tris-HCl pH 8.8, 16.6 mM
(NH4)2SO4, 1.5–6.7 mM MgCl2, 0.17 mg bovine serum albumin (Sigma,
U.K.) per ml, and 10 mM 2-mercaptoethanol], 10 nmol of each dNTP,
20 pmol of each primer in a total volume of 50 µl. After an initial
denaturation at 94°C for 2 min, 2.5 units of Taq polymerase (Promega)
was added followed by 35 cycles of 94°C for 10 s, 55–64°C for 10 s, 72°C
for 1 min, with a final incubation of 72°C for 5 min. The magnesium
chloride concentration and annealing temperature varied depending on the
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Table I. Primers used for the four nested RT-PCR reactions
Name Sequence (59→39) Positiona Productb
COL1A TGGGCTCGGACCTGCCAAGGCCACCGC –82–(– 56)
COL1B CCAGTGCAGAAGGAAGCCCTGCGCTCT 2674–2700 Fragment 1
COL1Cc ATGACGCTGCGGCTTCTGGTGGCCGCG 1–27 Exons 1–19
COL1D GGAGCCTCAGGCGGCGTAGTGACAACA 2574–2600 2600 bp
COL2A GGCAGAGAGGAGGGCCCTGCTGCAGTC 2008–2034
COL2B GGGGCCAGGGTCTCCAGGAAGAACCAA 4735–4761 Fragment 2
COL2Cc TCTGTCACCATTACCTGGACCAGGGT 2101–2126 Exons 16–48
COL2D AGCTCCTCTGGGCCCAGCGGGCCCCAC 4675–4701 2601 bp
COL3A TGGACCTCGTGGACCACTGGGGGACCC 4128–4154
COL3B GACAGGGCCAGGCAGACCTGGTGACCC 6832–6858 Fragment 3
COL3Cc GGTGACAAAGGCGATCGTGGGGAGCG 4198–4223 Exons 37–86
COL3D TCCACTGGCACCATCTCGACCTGGGGC 6772–6798 2601 bp
COL4A GAGATGGCCCTCCTGGACTCCCTGGAA 6221–6247
COL4B GTTCTGCTGAGACCCCGACTCCTCCAG 8868–8892 Fragment 4
COL4Cc CCTGGACTCTCTGGAGAACAGGGACCC 6301–6326 Exons 76–118
COL4D TCAGTCCTGGGCAGTACCTGTCCCCTG 8809–8835 2535 bp
aPosition according to Christiano et al, 1994b.
bLength excluding the T7 primer sequence as described above.
cPrefaced by T7 bacteriophage promoter sequence and consensus eukaryotic translation initiation signal: GGATCCTAATACGACTCACTATAGGAACAGACCACCATG
primer set used. Five microliters of the PCR assay was electrophorezed in
a 1% agarose minigel containing ethidium bromide. Products were purified
by the GENECLEAN method (Anachem, U.K.), and directly sequenced
using dRhodamine dye terminators on an ABI 377 genetic analyzer (Perkin
Elmer, Foster City, CA).
Solid phase fluorescent CCM strategy Primers used for the 21
genomic PCR assays are presented in Table II. Following informed
consent, genomic DNA was extracted from 0.5 to 5 ml peripheral blood
using standard methods. Amplification from genomic DNA was performed
as described above with the addition of biotinylated primers for control
PCR, and 50 pmol of R110 or R6G fl-dUTP’s (Perkin Elmer) in a total
volume of 50 µl. Control PCR products were purified by the GENE-
CLEAN method (Anachem) and made up to their original PCR volume
(i.e., 50 µl) with dH2O. Ten microliters of patient DNA was mixed with
4 µl of purified control DNA in a total volume of 30 µl containing
hybridization buffer (30 mM NaCl, 10 mM Tris-HCl pH 8), covered with
50 µl mineral oil and heated to 95°C for 5 min followed by cooling of
2°C/min to 65°C with a further incubation of 65°C for 45 min. For each
hybrid 10 µl of streptavidin coated paramagnetic beads (Promega) was
prepared by washing twice in 13 binding and washing buffer (BWB – 5 mM
Tris-HCl pH 7.5, 0.5 mM EDTA, 1 M NaCl) and making up to 30 µl
with 2 3 BWB. The washed beads were mixed with the hybridization
reaction and incubated at 30°C for 15 min. The beads were bound to the
magnet and the oil and supernatant removed. The beads were resuspended
with 20 µl of either 4 M hydroxylamine/2.3 M diethylamine or 0.4%
osmium tetroxide/2% pyridine and incubated at 37°C for 2 h (hydroxyl-
amine modification) or 25°C for 10 min (osmium modification). The
beads were washed with 25 µl dH2O and air-dried. Mismatches were
cleaved by resuspending the beads with 5 µl of 20% piperidine in formamide
loading dye followed by heating at 92°C for 10 min and snap-chilled on ice.
Two microliters of the piperidine treated mismatches were loaded onto
a 12 cm well-to-read 6% denaturing acrylamide gel on an ABI 377 genetic
analyzer along with ROX2500 markers (Fig 2). Analysis was performed
using the Genescan software version 2.1 (Perkin Elmer).
CSGE strategy Heteroduplex analysis was performed as previously
described (Christiano et al, 1997a). Briefly genomic DNA was isolated
from blood lymphocytes and subjected to 72 separate PCR amplifications.
Unpurified PCR products were heated and cooled to form a heteroduplex,
run on a CSGE gel, and visualized with ethidium bromide. Any fragment
with a different mobility to that of a control was sequenced using
dRhodamine dye terminator technology on an ABI 310 capillary system
(Perkin Elmer).
RESULTS
The protein truncation test strategy assays COL7A1 tran-
scripts in only four overlapping fragments The assay was
designed and initially developed using total RNA extracted from
normal control blood samples. To greatly reduce the number of
RT-PCR assays necessary to screen the entire COL7A1 reading
frame, the COL7A1 cDNA was divided into four overlapping
fragments of 2.6 kb in size, which, following transcription and
translation, would correspond to protein fragments of 90 kDa with
overlaps of 18 kDa. The primers for the four cDNA fragments
were designed to all have annealing temperatures of 65°C to enable
their simultaneous amplification. Using Taq Plus Long (Stratagene)
each assay yielded PCR products of the correct size. The assay was
then further optimized for recessive DEB patient blood samples by
increasing the concentration of total RNA used in the RT stage
to compensate for the reduction of COL7A1 transcripts due to
nonsense-mediated mRNA decay.
The optimized procedure (Fig 1) was used to screen blood
lymphocyte total RNA from 13 unrelated patients with generalized
recessive DEB (patients 1–13; Table III). Amplification of RT-
PCR fragment 3 failed for patients 3 and 7 and this was probably
due to the very small volumes of blood used for the RNA isolation
(0.5 ml). All RT-PCR products that amplified appeared to be of
the correct size (2.6 kb) by agarose gel electrophoresis and were
then analyzed by the protein truncation test. At least one aberrant
protein band was detected for each patient using SDS-PAGE.
The size of each aberrant protein band was calculated (Whittock
et al, 1997) and the respective secondary RT-PCR fragments
sequenced as described in Materials and Methods. Using this pro-
cedure a total of 15 mutated alleles were characterized in a total of
13 patients (Table III), which would be expected to yield a total
of 26 mutated alleles and these were confirmed at the genomic
level. Three of these were nonsense mutations, and five were
deletions of one or two base pairs leading to downstream PTC.
Three of these mutations have not been published previously
(R525X, 2785delAC, and 7178delT). Upon subsequent screening
of these patients using fl-CCM (see below) the following mutations
were not detected by the PTT: 650111 G→C (patient 4), 657311
G→A (patient 5), 3839delC and 6501 G→A (patient 9), and
4095delG (patient 10). Furthermore, upon sequencing it was found
that several aberrant protein bands were due to alternately spliced
COL7A1 transcripts and when the genomic DNA was sequenced
no mutations were found. The inclusion of all of intron 19 in
fragment 1 was seen in several patients as well as the splicing out
of exons 104 and 105 in fragment 4, and these were the cause of
the false positive results. This alternate splicing, however, was not
detected using control samples.
The solid phase Fl-CCM strategy assays the COL7A1 gene
in only 21 fragments The assay was initially developed (Fig 2)
using genomic DNA from six patients (patients 2–7; Table III)
known to be heterozygous for the common British mutation
7786delG (Mellerio et al, 1997). Fragment 19 covering exons 103–
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Figure 1. Schematic representation of the principles of the COL7A1
nested RT-PCR protein truncation test. Normal and mutant COL7A1
transcripts are represented. The point mutations in the mutant transcript are
represented by X and Y. Total cellular RNA isolated from blood lymphocytes
is subjected to four separate RT reactions using COL7A1 specific primers,
followed by four separate nested PCR denoted F1–F4. In addition to the
COL7A1 specific sequence, each 59 secondary PCR primer contains
consensus sequences for the T7 bacteriophage RNA promoter and a
eukaryote initiation codon (ATG). Unpurified PCR products for fragments
1–4 are transcribed and translated using a T7 coupled rabbit reticulocyte
lysate system and analyzed using discontinuous SDS-PAGE and
autoradiography. M, protein markers. Lanes 1–4 denote the four protein
bands F1–F4 transcribed and translated from the normal transcript, and lanes
6–9 denote the four protein bands for the mutant transcript. Aberrant protein
bands can be seen for the mutant transcript in lane 6 (F1) and lane 9 (F4)
corresponding to the heterozygotes R578X(X) and 7786delG(Y),
respectively.
108 was amplified for each patient along with a negative control
and subjected to chemical cleavage of mismatch. Upon analysis the
six patients possessed the correct mismatch peaks at 458 bp and
1082 bp on their electropherograms and the negative control
sample was uncleaved (Fig 3).
The entire 21 fragment fl-CCM procedure was then validated
on 27 DEB patients consisting of nine dominant and 18 recessive
DEB whose mutations had previously been characterized using the
CSGE procedure (patients 6, 7, 11–35; Table III). Cleavage bands
of the expected sizes were readily detected for 41 of the 45 mutated
alleles; however, the mutations 3948insT (patient 26), 497insA
(patient 27), 690014A→G (patient 31), and G2674D (patient 32)
were repeatedly not detected.
The fl-CCM protocol was then used to screen a further 23
recessive DEB patients (patients 2–5, 8, 10, 36–52; Table III) with
only one previously characterized mutation as detected on CSGE.
A total of 20 of 23 of these already identified mutated alleles were
readily detected. Of note, however, the mutations 497insA (patient
36), 8439A→G (patient 39), and 4524insT (patient 48) were not
detected. Nevertheless, the fl-CCM protocol did identify a further
13 of 23 mutations not previously detected by the CSGE procedure,
and these were 650111 G→C (patient 4), 657311 G→A (patient
5), 4095delG (patient 10), G2191S (patient 37), 7344 G→A (patient
38), 498011 G→T (patient 42), G2740A (patient 44), 618011
G→A (patient 45), R1632X (patient 46), R1772W (patient 47), 520
G→A (patient 49), G2263V (patient 50), and G2775S (patient 52).
In a comparative study, Fl-CCM is more sensitive than
CSGE In the comparative studies described above a total of 50
patients (nine dominant and 41 recessive DEB) were screened both
with fl-CCM and with CSGE. Of the possible 91 mutated alleles
the fl-CCM procedure detected 74 (81%) and the CSGE procedure
detected 68 (75%); however, the detection rates for fl-CCM and
CSGE were not statistically significant (χ2-test, 1 d.f., p 5 0.37).
In separate blind studies Fl-CCM shows a higher sensitivity
of detection compared with CSGE The fl-CCM procedure
was then used to screen 11 patients consisting of one dominant
and 10 recessive DEB (patients 9, 53–62; Table III), which had
not previously been screened for mutations using CSGE. A total
of 19 mutated alleles were detected from a possible 21 yielding a
sensitivity of 90%. Also, the CSGE procedure was used to screen
a further 31 patients consisting of seven dominant and 24 recessive
DEB (patients 63–93; Table III), which had not previously been
screened. A total of 45 of the possible 55 mutated alleles were
detected yielding a sensitivity of 82%.
The detection rates for these two separate blind studies were not
significantly different (χ2-test, 1 d.f., p 5 0.40).
Combining two or more mutation detection strategies allows
for very high throughput and sensitivity The three techniques
have been used to screen a total of 93 patients consisting of 17
dominant and 76 recessive DEB. A total of 147 mutated COL7A1
alleles have been detected out of a possible 169 yielding an overall
detection sensitivity of 87%. A total of 79 different mutations have
been detected in this study of which 10 are nonsense mutations,
17 splicing mutations, 19 deletions, eight insertions, two deletion/
insertions, 20 glycine substitutions, and three other missense
mutations. Fifty-seven of these mutations have not been previously
published (Table IV).
DISCUSSION
We have developed two very different strategies for the detection
of mutations in COL7A1. The first uses blood lymphocyte total
RNA as the template for a nested RT-PCR protein truncation test
(PTT). The second uses genomic DNA as the template for solid-
phase fluorescent chemical cleavage of mismatch (fl-CCM).
The RT-PCR PTT procedure scans the entire open reading
frame for protein terminating mutations in only four overlapping
nested RT-PCR fragments of 2.6 kb each in size. In this study, 13
recessive DEB patients were screened with a detection sensitivity
of 58% (15 of 26). RNA-based PTT strategies using blood
lymphocyte total RNA have been successfully applied to many
diseases including Duchenne muscular dystrophy (dystrophin)
(Roest et al, 1993b; Gardner et al, 1995; Whittock et al, 1997),
cystic fibrosis (CFTR) (Romey et al, 1996), and Fanconi anaemia
A (FAA) (Lo Ten Foe et al, 1996). A major disadvantage with
blood lymphocyte total RNA in this study, however, was the
detection of false negative and false positive results generated
through the processing of alternately spliced transcripts. This
phenomenon is greatly increased for COL7A1 due to the very
large number of exons present. Although not always available, the
use of specific tissues can greatly enhance the sensitivity and
specificity of the RT-PCR stage such as the use of muscle RNA
for dystrophin transcripts (Whittock et al, 1997). Therefore, total
RNA extracted from skin would be expected to have increased
concentrations of correctly spliced COL7A1 transcripts that should
greatly reduce or even eliminate the problem of false positive and
false negative truncations. Skin biopsies are routinely taken for
immunohistochemistry and electron microscopy as diagnostic
studies in some DEB patients and a small portion of this could be
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Table II. Primers used for the 21 genomic PCR assays
Primer Exons Sequence (59→39) Positiona Product (bp) Annealing temperature
(°C)
1F 1–2 GCGCAGGCAAGACCAGGACT 3751–3770 1010 58
1R TTTCTGCAAAGACCTGGCCT 4741–4760
2F 3–8 AGAGCCTGATACCCGTAACC 5228–5247 1543 58
2R TGCATGGGGGACACCAAGGG 6751–6770
3F 9–12 ACAGCCTCCTGGTGGCCTGG 6601–6620 1120 58
3R ACAGTTCAGGGCTCAGTGCC 7701–7720
4F 13–16 TCTGCGTCCCTGTCCATCAC 8121–8140 1410 58
4R TCCAGGGCTAGCAAACTCTG 9511–9530
5F 17–20 CAGGTCAGGGTGGAATGGGG 9451–9470 1390 64
5R CCCAGTGACAGACCCCGCCC 10821–10840
6F 21–24 CAGTGAGGATGAGGAAGATC 10941–10960 1200 58
6R GGGAGAATGCCTGAACCTAT 12121–12140
7F 25–31 ATAGATAGGGTTTGGTCACA 12211–12230 1340 58
7R AATTCCGATGATTCTAACTC 13531–13550
8F 32–39 GGGTCAGTGGGGTAGGCGAC 13781–13800 1604 55
8R CTGAAGGAGAAACACACGCG 15365–15384
9F 40–46 GCTGACTTGATGATGTCCCA 15291–15310 1490 58
9R TCACGGGCCCAGCACTGTGG 16761–16780
10F 47–52 GCTGTATGACTTCCAATTCC 16954–16973 1037 58
10R TCTGAGCAGCAGCTGGACAG 17971–17990
11F 53–57 ATCCATCCACTCCCTGCCTC 17951–17970 1380 61
11R CTCCCTGTGGCAGAGATAAG 19311–19330
12F 58–64 CTGTGGGTGGAGGGTAAGAA 19221–19240 1550 58
12R TGTGTCTACACGTGTGCCTC 20751–20770
13F 65–70 CAGTTGCCTGTTGGGGTGAG 21751–21770 1160 58
13R TGTCCCCACTGCCCAAGTTC 22891–22910
14F 71–75 GAACTTGGGCAGTGGGGACA 22891–22910 1290 58
14R CCCTTGAGTCCAGGGGGTCC 24161–24180
15F 76–82 TGTGTGCCATAACCCTGGAA 24001–24020 1570 58
15R CTCATTGCAGGAGATGACAG 25551–25570
16F 83–91 GTGTGCGCCAACCTCCTGGG 25531–25550 1550 58
16R GACTCAGGGGCTCAGACATG 27061–27080
17F 92–94 ATGGTCACATCAGAACTCCC 27601–27620 620 58
17R CCTACCCTCTGCCCCCTCAA 28201–28220
18F 95–102 GTGAATCCATGGTGGGTGAG 28151–28170 1550 58
18R GAAAGCCTCCTCCTGTCCTC 29681–29700
19F 103–108 GGGCCGTTCGGGAGTGACTT 30011–30030 1540 58
19R ACCTTGACACCTCGAGACCA 31531–31550
20F 109–113 GGGCATTAGGCCAGGGAGCT 31691–31710 1120 58
20R CCCCATCTTCTTGACTGCTT 32791–32810
21F 114–118 TATCTCTACCCCCTCTGCCT 33211–33230 1460 58
21R GTGCACACAAGCCTCTAGCA 34651–34670
aNucleotide position within the COL7A1 gene according to Christiano et al, 1994a.
Figure 2. Schematic representation of the principles
of the COL7A1 solid phase fluorescent chemical
cleavage of mismatch strategy. One of the fragments
for patient and control is represented. The sequence change
in the patient fragment is represented by X. Genomic DNA
is isolated from blood lymphocytes and subjected to 21
separate fluorescent PCR ranging in size from 620 bp to
1604 bp. The control PCR utilizes biotin-labeled primers
as indicated.Patient and controlDNA (probe) is hybridized
to form two heteroduplexes (stage 1), which are then
bound along with any probe homoduplex to streptavidin
beads via the biotin molecules in order to remove any
patient homoduplexes formed. Any mismatches are modi-
fied (stage2)usingeitherhydroxylamineorosmiumtetrox-
ide, and the DNA is cleaved (stage 3) at the mismatch site
by the use of piperidine. Cleavage products are eluted
(stage 4) from the beads and electrophoresed through a 6%
acrylamide gel (stage 5) on an ABI 377 genetic analyzer
and analyzed using Genescan software.
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Table III. Patient mutations detected in this studya
Mutations
Patient no. Diagnosis Exon(s) Allele 1 Allele 2 Consequences
1 HS-RDEB 34/– R1340X ND PTC/–
2 HS-RDEB 104/– 7786delG ND PTC/–
3 non HS-RDEB gen 104/– 7786delG ND PTC/–
4 HS-RDEB 79/104 650111 G→C 7786delG In frame deletion/PTC
5 HS-RDEB 81/104 657311 G→A 7786delG PTC/PTC
6 HS-RDEB 13/104 R578X 7786delG PTC/PTC
7 non HS-RDEB loc 64/104 553211 G→A 7786delG PTC/PTC
8 non HS-RDEB loc 73/– 6081delC ND PTC/–
9 non HS-RDEB gen 31/79 3839delC 6501 G→A PTC/In frame deletion
10 HS-RDEB 13/35 R578X 4095delG PTC/PTC
11 HS-RDEB 12/13 R525X R578X PTC/PTC
12 HS-RDEB 21/31 2785delAC 3839delC PTC/PTC
13 HS-RDEB 94/94 7178delT 7178delT PTC/PTC
14 DDEB 73 G2043R GS
15 DDEB 73 G2046 V GS
16 DDEB 93 G2369S GS
17 DDEB 61 G1776R GS
18 DDEB 85 G2242R GS
19 DDEB 73 G2043R GS
20 DDEB 110 G2713R GS
21 DDEB 113 R2791W Missense
22 DDEB 62 G1791E GS
23 non HS-RDEB gen 49/115 4783–1 G→A 8441–14del21 PTC/PTC
24 non HS-RDEB gen 19/19 2470insG 2470insG PTC/PTC
25 HS-RDEB 3/5 425 A→G Q189X PTC/PTC
26 HS-RDEB 19/32 2470insG 3948insT PTC/PTC
27 HS–RDEB 4/5 497insA 68211G→A PTC/PTC
28 non HS-RDEB gen 56/69 G1703E 5772delG GS/PTC
29 non HS-RDEB gen 19/19 2470insG 2470insG PTC/PTC
30 HS-RDEB 49/115 4783–1 G→A 8441–14del21 PTC/PTC
31 HS–RDEB 15/87 R682X 690014 A→G PTC/PTC
32 non HS-RDEB gen 13/108 R578X G2674D PTC/GS
33 non HS-RDEB gen 19/19 2470insG 2470insG PTC/PTC
34 HS-RDEB 13/31 R578X 3839delC PTC/PTC
35 HS-RDEB 13/72 R578X R1933X PTC/PTC
36 HS-RDEB 4/– 497insA ND PTC/–
37 non HS-RDEB gen 73/81 6081delC G2192S PTC/GS
38 non HS-RDEB gen 95/104 7344 G→A 7786delG PTC/PTC
39 HS-RDEB 6/116 847–6 G→A 8439 A→G PTC/PTC
40 non HS-RDEB gen 13/– R578X ND PTC/–
41 HS-RDEB 117/– 8697del11 ND PTC/–
42 HS–RDEB 54/104 498011 G→T 7786delG PTC/PTC
43 HS-RDEB 54/– 5048insGAAA ND PTC/–
44 HS-RDEB 104/110 7786delG G2740A PTC/GS
45 HS–RDEB 73/115 618011 G→A R2814X PTC/PTC
46 HS-RDEB 51/115 R1632X R2814X PTC/PTC
47 non HS-RDEB gen 61/104 R1772W 7786delG PTC/Missense
48 HS-RDEB 44/– 4524insT ND PTC/–
49 HS-RDEB 4/117 520 G→A 8760delG PTC/PTC
50 non HS-RDEB gen 13/86 R578X G2263 V PTC/GS
51 non HS-RDEB gen 115/– 8441–14del21 ND PTC/–
52 non HS-RDEB gen 112/117 G2775S 8760delG GS/PTC
53 HS-RDEB 36/36 4172insC 4172insC PTC/PTC
54 HS-RDEB 95/115 7288del29 R2814X PTC/PTC
55 HS-RDEB 54/67 5031ins9 5657delA In frame ins/PTC
56 HS-RDEB 14/14 1781–1 G→C 1781–1 G→C PTC/PTC
57 HS-RDEB 5/52 579delC 4918delG PTC/PTC
58 non HS-RDEB gen 73/94 R2008G Q2417X Mis/PTC
59 HS-RDEB 115/– 8441–14del21 ND PTC/–
60 HS–RDEB 79/– 650111 G→C ND In frame deletion/–
61 non HS-RDEB gen 50/72 G1604R 5964insC GS/PTC
62 DDEB 73 G2043R GS
63 DDEB 45 G1522E GS
64 DDEB 73 G2006 A GS
65 DDEB 73 G2040D GS
66 DDEB 73 G2043R GS
67 DDEB 73 G2043R GS
68 DDEB 73 G2046 V GS
69 DDEB 87 6863del16 PTC
70 non HS-RDEB gen 58/78 R1730X G2132D PTC/GS
71 non HS-RDEB gen 55/117 5097 G→A G2775S In frame deletion/GS
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Table III. Continued
Mutations
Patient no. Diagnosis Exon(s) Allele 1 Allele 2 Consequences
72 non HS-RDEB gen 13/75 R578X G2073D PTC/GS
73 non HS-RDEB gen 41/61 4429delG G1782R PTC/GS
74 HS-RDEB 49/49 4767delA 4767delA PTC/PTC
75 non HS-RDEB gen 19/19 2470insG 2470insG PTC/PTC
76 HS-RDEB 13/115 R578X 8441–14del21 PTC/PTC
77 HS-RDEB 49/49 4738del3insA 4738del3insA PTC/PTC
78 HS-RDEB 3/4 425 A→G 497insA PTC/PTC
79 non HS-RDEB gen 19/19 2470insG 2470insG PTC/PTC
80 non HS-RDEB gen 31/95 3839delC 7344 G→A PTC/PTC
81 non HS-RDEB gen 19/19 2470insG 2470insG PTC/PTC
82 non HS-RDEB gen 19/19 2470insG 2470insG PTC/PTC
83 HS-RDEB 13/104 1637–1 G→A 7786delG PTC/PTC
84 HS-RDEB 117/– 8697del11 ND PTC/–
85 HS-RDEB 13/– R578X ND PTC/–
86 HS-RDEB 39/– 4317delC ND PTC/–
87 non HS-RDEB gen 95/– 7310del6ins25 ND PTC/–
88 non HS-RDEB gen 19/– 2470insG ND PTC/–
89 HS-RDEB 73/– 6041delAG ND PTC/–
90 HS-RDEB 69/– 5772delG ND PTC/–
91 non HS-RDEB gen 95/– 7344 G→A ND PTC/–
92 non HS-RDEB gen 104/– 7786delG ND PTC/–
93 non HS-RDEB gen 19/– 2470insG ND PTC/–
aHS-RDEB, Hallopeau-Siemens recessive dystrophic EB; non HS-RDEB gen, Generalized recessive dystrophic EB, non Hallopeau-Siemens subtype; non HS-RDEB loc,
Localized recessive dystrophic EB, non Hallopeau-Siemens subtype; DDEB, Dominant dystrophic EB; ND, not determined; PTC, premature termination codon; GS, glycine
substitution.
Figure 3. Fluorescent CCM analysis of COL7A1 demonstrating the mutation 7786delG. Electropherogram generated by the Genescan software of
fragment 19 (exons 103–108) for two patients heterozygous for the common British mutation 7786delG (lanes 1 and 2) and a negative control (lane 3). Lane 4
contains the ROX2500 DNA size standards. Cleavage peaks can be seen for the 7786delG mutation (458 bp 1 1082 bp) in lanes 1 and 2, but are absent for
the negative control. The full-size uncleaved DNA peak is 1540 bp.
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Table IV. COL7A1 mutations published to date including this study
I. Nonsense mutations
Exon cDNA sequence changea Amino acid changea Denoted Reference
5 553 C→T Arg 185→Term R185X Hovnanian et al, 1997
5 565 C→T Gln 189→Term Q189X This study
5 676 C→T Arg 226→Term R226X Christiano et al, 1996a
6 706 C→T Arg 236→Term R236X Hovnanian et al, 1994
6 751 C→T Gln 251→Term Q251X Christiano et al, 1996b
6 841 C→T Gln 281→Term Q281X Hovnanian et al, 1997
7 933 C→A Tyr 311→Term Y311X Christiano et al, 1995a
12 1573 C→T Arg 525→Term R525X This study
13 1732 C→T Arg 578→Term R578X Dunnill et al, 1994
15 2044 C→T Arg 682→Term R682X This study
18 2387 G→A Trp 796→Term W796X Christiano et al, 1996b
18 2388 G→A Trp 796→Term W796X Christiano et al, 1994a
34 4018 C→T Arg 1340→Term R1340X Hovnanian et al, 1994
34 4027 C→T Arg 1343→Term R1343X Hovnanian et al, 1994
51 4894 C→T Arg 1632→Term R1632X This study
58 5188 C→T Arg 1730→Term R1730X This study
72 5797 C→T Arg 1933→Term R1933X This study
72 5932 C→T Arg 1978→Term R1978X Footnote 1
83 6646 G→T Gly 2216→Term G2216X Hovnanian et al, 1997
94 7249 C→T Gln 2417→Term Q2417X This study
97 7411 C→T Arg 2471→Term R2471X Christiano et al, 1996c
104 7828 C→T Arg 2610→Term R2610X Hovnanian et al, 1997
115 8440 C→T Arg 2814→Term R2814X Christiano et al, 1996b
116 8569 G→T Glu 2857→Term E2857X Shimizu et al, 1996
II. Glycine substitutions and missense mutations
Exon cDNA sequence change Amino acid change Denoted Reference
34 4039 G→C Gly 1347→Arg G1347R Terracina et al, 1998
44 4556 G→A Gly 1519→Asp G1519D Hammami-Hanasli et al, 1998b
45 4565 G→A Gly 1522→Glu G1522E This study
48 4669 G→A Gly 1557→Arg G1557R Christiano et al, 1996c
50 4810 G→A Gly 1604→Arg G1604R This study
53 4954 G→A Gly 1652→Arg G1652R Cserhalmi-Friedman et al, 1997
56 5108 G→A Gly 1703→Glu G1703E This study
61 5314 C→T Arg 1772→Trp R1772 W This study
61 5326 G→A Gly 1776→Arg G1776R This study
61 5344 G→A Gly 1782→Arg G1782R Christiano et al, 1996d
61 5372 G→A Gly 1791→Glu G1791E This study
72 5944 G→T Gly 1982→Trp G1982 W Hovnanian et al, 1997
73 6007 G→A Gly 2003→Arg G2003R Christiano et al, 1996e
73 6018 G→C Gly 2006→Ala G2006 A This study
73 6017 G→A Gly 2006→Asp G2006D Hammami-Hanasli et al, 1998a
73 6022 C→G Arg 2008→Gly R2008G Hovnanian et al, 1997
73 6022 C→T Arg 2008→Cys R2008C Kon et al, 1998
73 6025 G→A Gly 2009→Arg G2009R Winberg et al, 1997
73 6044 G→A Gly 2015→Glu G2015E Hammami-Hauasli et al, 1998a
73 6074 G→C Gly 2025→Ala G2025 A Hovnanian et al, 1997
73 6100 G→A Gly 2034→Arg G2034R Kon et al, 1997a
73 6100 G→T Gly 2034→Trp G2034 W Rouan et al, 1998
73 6110 G→A Gly 2037→Glu G2037E Jonkman et al, 1999
73 6118 G→A Gly 2040→Ser G2040S Christiano et al, 1994c
73 6119 G→A Gly 2040→Asp G2040D This study
73 6119 G→T Gly 2040→Val G2040 V Rouan et al, 1998
73 6127 G→A Gly 2043→Arg G2043R Christiano et al, 1995c
73 6127 G→T Gly 2043→Trp G2043 W Mecklenbeck et al, 1999
73 6137 G→T Gly 2046→Val G2046 V This study
73 6146 G→A Gly 2049→Glu G2049E Hovnanian et al, 1997
73 6164 G→A Gly 2055→Glu G2055E Christiano et al, 1996c
74 6187 C→G Arg 2063→Gly R2063G Hovnanian et al, 1997
74 6187 C→T Arg 2063→Trp R2063 W Hovnanian et al, 1997
74 6190 G→A Gly 2064→Arg G2064R Rouan et al, 1998
75 6218 G→A Gly 2073→Asp G2073D Dunnill et al, 1996
75 6227 G→A Gly 2076→Asp G2076D Kon et al, 1997a
75 6235 G→A Gly 2079→Arg G2079R b
75 6236 G→A Gly 2079→Glu G2079E Kon et al, 1997b
78 6395 G→A Gly 2132→Asp G2132D This study
82 6574 G→A Gly 2192→Ser G2192S This study
83 6619 G→A Gly 2207→Arg G2207R b
85 6716 G→A Gly 2239→Asp G2239D c
85 6724 G→A Gly 2242→Arg G2242R Lee et al, 1997
85 6725 G→A Gly 2242→Glu G2242E c
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Table IV. Continued
Exon cDNA sequence change Amino acid change Denoted Reference
86 6752 G→A Gly 2251→Glu G2251E Hammami-Hanasli et al, 1998b
86 6788 G→T Gly 2263→Val G2263 V This study
91 7042 G→C Gly 2347→Arg G2347R Cserhalmi-Friedman et al, 1999
91 7051 G→A Gly 2351→Arg G2351R Christiano et al, 1996f
92 7096 G→A Gly 2366→Ser G2366S Hashimoto et al, 1999
93 7105 G→A Gly 2369→Ser G2369S Mellerio et al, 1999
94 7184 G→A Gly 2395→Asp G2395D d
103 7705 G→C Gly 2569→Arg G2569R Christiano et al, 1996c
103 7723 G→A Gly 2575→Arg G2575R Shimizu et al, 1996
105 7867 G→T Gly 2623→Cys G2623C Christiano et al, 1995c
107 7957 G→A Gly 2653→Arg G2653R Christian et al, 1996c
108 8012 G→T Gly 2671→Val G2671 V Kon et al, 1997b
108 8020 G→C Gly 2674→Arg G2674R Christiano et al, 1996c
108 8021 G→A Gly 2674→Asp G2674D This study
110 8137 G→A Gly 2713→Arg G2713R This study
110 8138 G→A Gly 2713→Asp G2713D Rouan et al, 1998
110 8219 G→C Gly 2740→Ala G2740A This study
111 8245 G→A Gly 2749→Arg G2749R Christiano et al, 1996c
112 8323 G→A Gly 2775→Ser G2775S Kon et al, 1998
113 8371 C→T Arg 2791→Trp R2791W This study
113 8393 T→A Met 2798→Lys M2798K Christiano et al, 1993
III. Splicing mutations
IVS/Exon cDNA position Donor/acceptor Reference
IVS 2 86–3 C→G Acceptor –3 Hovnanian et al, 1997
Exon 3 425 A→G Donor –2 Gardella et al, 1996
IVS 3 427–3 C→G Acceptor –3 Kon et al, 1998
Exon 4 520 G→A Donor –1 This study
IVS 5 68211 G→A Donor 11 Hovnanian et al, 1997
IVS 7 847–6 G→A Acceptor –6 This study
IVS 13 1637–1 G→A Acceptor –1 This study
IVS 14 1781–1 G→C Acceptor –1 This study
IVS 35 4048–1 G→C Acceptor –1 Christiano et al, 1997c
Exon 35 4118 C→T Donor –2 d
IVS 35 411911 G→T Donor 11 Kon et al, 1998
IVS 49 4783–1 G→A Acceptor –1 This study
IVS 53 498011 G→T Donor 11 This study
Exon 55 5097 G→A Donor –1 This study
IVS 64 5532 1 1 G→A Donor 11 Mellerio et al, 1999
IVS 69 5771–2 A→C Donor –2 Kon et al, 1998
Exon 70 5820 G→A Donor –1 Terracina et al, 1998
IVS 73 6180 1 1 G→A Donor 11 This study
IVS 74 6216 1 5 G→T Donor 15 Kon et al, 1998
Exon 79 6501 G→A Donor –1 This study
IVS 79 6501 1 1 G→C Donor 11 Christiano et al, 1996b
IVS 81 6573 1 1 G→A Donor 11 This study
IVS 81 6573 1 1 G→C Donor 11 Tamai et al, 1997
IVS 82 6619–2 A→T Acceptor –2 Christiano et al, 1996d
IVS 87 6900 1 4 A→G Donor 14 This study
Exon 95 7344 G→A Donor –1 Gardella et al, 1996
IVS 106 7876–1 G→C Acceptor –1 Hovnanian et al, 1997
Exon 108 8045 A→G Donor –2 Kon et al, 1998
Exon 114 8439 A→G Donor –2 This study
IV. Deletion and insertion mutations
Exon cDNA change Reference
2 111insA Christiano et al, 1996a
2 154delG Footnote 4
2 189delG Christiano et al, 1997a
3 325insCG Hovnanian et al, 1997b
4 497insA Christiano et al, 1996a
5 521del7 Hovnanian et al, 1997b
5 579delC This study
5 642delGT Christiano et al, 1997b
7 847–6del5 Hovnanian et al, 1997b
7 884delG Christiano et al, 1996b
9 1172delAT Christiano et al, 1994a
10 1344insGC This study
12 1592del11ins25 Hilal et al, 1993
14 1898delG Christiano et al, 1996d
19 2470insG Christiano et al, 1996f
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Table IV. Continued
Exon cDNA change Reference
20 2638del25 Hammami-Hauasli et al, 1997
21 2785delAC This study
31 3839delC This study
31 3858delG Christiano et al, 1994a
32 3948insT Salas-Alanis et al, 1998
35 4095delG This study
36 4172insC This study
39 4317delC This study
41 4429delG This study
44 4524insT This study
49 4738del3insA This study
49 4767delA This study
52 4918delG This study
54 5014delA Kon et al, 1998
54 5031ins9 This study
54 5048insGAAA This study
55 5092delG Christiano et al, 1996d
56 5103delCCinsG Christiano et al, 1996c
67 5657delA This study
69 5772delG This study
70 5818delC Christiano et al, 1995a
72 5964insC This study
73 6041delAG This study
73 6075delC Christiano et al, 1996d
73 6081del28 Sakuntabhai et al, 1998
87 6847del27 Sakuntabhai et al, 1998
87 6863del16 Cserhalmi-Friedman et al, 1998
94 7178delT This study
95 7287del29 This study
95 7310del6ins25 This study
103 7729delC Christiano et al, 1996b
104 7786delG Dunnill et al, 1996
109 8068del17ins2 Footnote 4
109 8091delG Kon et al, 1998
115 8441–14del21 Dunnill et al, 1996
115 8523del14 Bruckner-Tuderman et al, 1995
117 8697del11 This study




VI. Summary of mutations
Mutation type Total number of mutations New mutations in this study
Nonsense mutations 24 7
Missense mutations 65 16
Splicing mutations 29 12
Deletions and insertions 53 22
Promoter mutations 1 0
TOTAL 172 57
aPosition according to Christiano et al, 1994b.
bRouan F, Pulkkinen L, Jonkman MF, Uitto J: Novel and recurrent glycine substitution mutations in COL7A1 in dystrophic epidermolysis bullosa: Genotype/phenotype
correlations. J Invest Dermatol 110:508 1998 (abstr.)
cTamai K, Hashimoto I, Murai T, et al: Particular mutations in exon 85 of type VII collagen gene (COL7A1) induce severe itch: Specific glycine substitutions for dominant forms
of epidermolysis bullosa pruriginosa. J Invest Dermatol 110:509, 1998 (abstr.)
dMayama M, Tamai K, Fukai K, et al: Analysis of type VII collagen gene (COL7A1) mutations in three Japanese cases of dystrophic epidermolysis bullosa (DEB). J Invest Dermatol
112:568, 1999 (abstr.)
used for RNA extraction. The PTT procedure described here has
several advantages over the CSGE technique currently used as only
16 primers are required to amplify the four overlapping fragments
compared with the 144 primers necessary for the CSGE procedure.
In addition, PTT only detects pathogenic truncating mutations and
therefore does not detect polymorphisms. Based on one SDS-
PAGE gel per day the entire open reading frame of COL7A1 can
be screened for five patients per day allowing a high throughput
screening procedure. Although in this study the PTT was only
used for screening recessive DEB patients, the test could be
modified slightly to screen mild recessive DEB patients as well as
parents and carriers of all recessive DEB patients by incorporating
the use of cycloheximide, which has been shown to stabilize
mRNA transcripts containing protein truncating mutations (Darling
et al, 1997, 1998). A major disadvantage, however, is that PTT
will not detect missense mutations that account for nearly all cases
of dominant DEB (.95%), and a smaller proportion of recessive
DEB (10%–15%).
The fl-CCM procedure scans the COL7A1 gene for all sequence
changes whether pathogenic or polymorphic. The COL7A1 gene
is amplified in 21 separate assays and analyzed for mismatches using
chemical cleavage of the DNA strands. Any cleavage products are
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then detected using fluorescent technology that can be used to
accurately locate any sequence change. In a comparative study,
fl-CCM and CSGE were used to screen for a total of 91 mutated
alleles in 50 DEB patients (nine dominant and 41 recessive).
Fluorescent CCM detected 81% of mutant alleles and CSGE
detected slightly less at 75%, although the difference was not
statistically significant. Both techniques failed, however, to detect
several different mutations that seem to be specific to each detection
procedure. The mutations not detected by fl-CCM procedure
generally involved mismatched A or T bases including single base
insertions, and the mutations missed by the CSGE procedure were
generally base substitutions. Several improvements to the CSGE
protocol have recently been published, which may increase the
sensitivity of detecting mutations in collagen genes (Korkko et al,
1998). These recommendations have yet to be implemented into
our routine screening protocol because much of the increased
sensitivity centres around reducing the size of the PCR fragments
screened to below 450 bp. In the case of COL7A1 this would lead
to a substantial increase in the number of PCR fragments to be
assayed. This would in turn increase both the cost and the workload
of this already demanding protocol.
Since its development, CCM (Cotton et al, 1988) has improved
in terms of both sensitivity and safety. The original procedure used
DNA probes that had been radioactively end-labeled permitting
the accurate location of the mutation within the DNA strand. This
strategy was successfully applied to the detection of mutations in
patients with the X-linked disorder human ornithine transcarba-
moylase deficiency (Grompe et al, 1989). Although the technique
was suggested to detect close to 100% of single base substitutions
(Forrest et al, 1991), the use of radioactivity with toxic chemicals
was far from ideal. Although other nonisotopic methods have been
reported (Saleeba et al, 1992), the introduction of fluorescent-based
gel technology has greatly improved the safety aspect of the
procedure. The DNA strand can now either be end-labeled using
fluorescently labeled primers (Verpy et al, 1994), or internally
labeled using fluorescently labeled dUTP’s (Rowley et al, 1995).
The use of solid phase technology and microtitre tube format
(Rowley et al, 1995), along with automated fluorescent analyzers,
now permits the rapid screening of large genes. In addition,
potassium permanganate and tetraethylammonium chloride have
been validated as safer alternatives to the highly toxic osmium
tetroxide (Roberts et al, 1997). Fluorescent CCM has been applied
to the screening of many diseases including Fanconi anaemia C
(FAC) (Gibson et al, 1996), Fabry disease (alpha-galactosidase A)
(Germain et al, 1996), and hereditary breast and ovarian cancer
(BRCA1) (Greenman et al, 1998). Although the fl-CCM protocol
may involve a few more stages than CSGE, this is easily outweighed
by its advantages. The number of primers required for the fl-CCM
PCR assays in COL7A1 is only 84 (42 standard and 42 biotinylated)
compared with 144 for CSGE. The Genescan analysis software can
locate the position of the sequence change compared with CSGE,
which does not give any indication of where the change is within
the fragment. This permits the sequencing of a very small region
of DNA to allow for the characterization of the mutation. Based
on running three fluorescent gels per day this fl-CCM protocol
can be used to screen the entire COL7A1 gene for mutations in
six patients per day. If the three different fl-dUTP’s (i.e., blue,
green, and yellow) are used to create a multiplex in each well of
the gel, however, this permits the use of an exceedingly high
throughput screening procedure in which the entire COL7A1 gene
can be screened for 18 patients per day (540 kb).
With the accumulation of mutation data for HS-RDEB patients,
it is now clear that base substitutions and small insertions/deletions
are not the sole causes of the disease. In a recent review (Jarvikallio
et al, 1997), mutations in approximately 88% (60 of 68) of HS-
RDEB COL7A1 alleles had been determined. This degree of
mutation detection sensitivity is supported by our study where the
combination of mutation screening techniques used has identified
a total of 147 of a possible 169 mutant alleles yielding a sensitivity
of 87%. Although the current techniques to screen for small
mutations are not 100% efficient, this cannot on its own explain
for the shortfall in the number of mutated alleles detected. One
explanation for this might be that the COL7A1 promoter region,
which is not covered by current screening strategies, may harbor
mutations. In fact a promoter mutation has already been detected
–96 bases (C→T) from the transcription initiation start site in a
patient compound heterozygous for an R1978X nonsense mutation
on the other COL7A1 allele (Tadini et al 1998).1 This promoter
mutation lies within a region with an Sp1 transcription factor
consensus sequence and would be expected to result in a lack of
COL7A1 transcript (Vindevoghel et al, 1997). TGF-beta responsive
elements have also been identified in the COL7A1 promoter
(Vindevoghel et al, 1998). Mutations in such sites might also have
pathogenic consequences in some patients with DEB. Therefore,
to further the detection of COL7A1 mutations, these regions
within the promoter should also be screened in any comprehensive
mutation detection strategy. In addition, there may be large-scale
exonic deletions or duplications akin to those found in the
dystrophin gene (Yau et al, 1996), which would be missed in
compound heterozygotes for a large and small mutation. These
large-scale abnormalities may have been undetected solely due to
the techniques used to screen for mutations in the type VII collagen
gene, which are based on the amplification of only a few exons at
a time. Very sensitive Southern blotting techniques or quantitative
fluorescent PCR therefore may reveal any large-scale abnormalities
within the COL7A1 gene.
As more is understood about the processes underlying the splicing
of pre-mRNA to mature mRNA, other apparently silent sequence
changes within the exons or introns of COL7A1 may also turn
out to be disease causing mutations. Splicing enhancers are purine
rich regions within exons and it has already been demonstrated
that a patient with an apparently lethal nonsense mutation (E1211X)
within exon 27 of the dystrophin gene presented with the nonlethal
Becker muscular dystrophy phenotype (Shiga et al, 1997). The base
substitution involved inserts a T into the purine rich sequence and
the exon is partially skipped avoiding the stop codon. Further
studies have demonstrated that mutations introducing a T into a
purine rich region within 30 bases of the nearest exon–intron
boundary lead to exon skipping (Valentine, 1998). It has also been
demonstrated that mutations in introns that affect sequences called
intron splice enhancers (ISE) lead to the skipping of exons
(McCarthy and Phillips, 1998). It is therefore very important never
to dismiss rare polymorphisms within either exons or introns,
especially if no other pathogenic mutations can be found within
the type VII collagen gene. Rather, it is important to study the
mRNA in that region and to determine whether exon skipping is
taking place. This phenomenon is a good reason to screen for
mutations using keratinocyte mRNA where possible rather than
genomic DNA.
The mutations described in this study (Table III) consist of 79
different mutations comprising 50 single base substitutions including
17 splice site mutations, 19 single base insertions or deletions, and
10 insertions or deletions of two or more bases. The common
British mutations R578X and 7786delG not surprisingly account
for the highest frequencies of mutations in this study (Table III).
Of the 152 RDEB alleles R578X is present in 11 (7%) and
7786delG is present in 12 (8%) supporting the conclusions of
Mellerio et al (1997) of targeting these two mutations in the British
RDEB patients before screening the entire COL7A1 gene.
One of the most common nonsense mutations in human genes
is caused by the hypermutability of 5-methyl-cytosine to thymine
at CpG dinucleotides. This leads to a C-to-T substitution and
when this occurs within the arginine codon, CGA, the result is a
premature termination codon TGA. Within the COL7A1 open
1Tadini G, Gardella R, Zoppi N, Ferraboli S, Barlati S, Colombi M:
Molecular characterization of twopatients affected by the Hallopeau-Siemens
variant of recessive epidermolysis bullosa dystrophica. J Invest Dermatol
110:510, 1998 (abstr.)
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reading frame there are a total of 30 CGA codons, which if mutated
could lead to premature stops. In this study, eight of these codons
were mutated (i.e., R525X, R578X, R682X, R1340X, R1632X,
R1730X, R1933X, and R2814X) and these mutations accounted
for 20 out of 152 RDEB alleles (13%). Other studies have identified
mutated CpG dinucleotides in a further seven arginine codons
(R185X, R226X, R236X, R1343X, R1978X, R2471X, and
R2610X; Table IV). These data support the rationale behind the
study conducted by Hovnanian et al (1994) where CGA codons
were specifically analyzed for C-to-T substitutions.
In this study we have detected 57 novel mutations (Table IV),
12 of which occur at splice sites and consist of eight donor and
four acceptor mutations. Four of the donor mutations, however,
occur within the last two bases at the 39 end of exons. Mutations
at the 39 end of exons, which cause alternate splicing of the type
VII collagen gene (COL7A1), were first described by Gardella et al
(1996) where mutations in the penultimate base of exon 3
(425 A→G) and the last base of exon 95 (7344 G→A) were
characterized. When first discovered, however, both mutations
were considered to be polymorphisms (Christiano et al, 1994b).
The consensus sequences for these positions in human genes has
been determined to be 78% for a G at donor position –1 and 58%
for an A at donor position –2 (Shapiro and Senapathy, 1987), and
therefore any change of base at these positions may lead to alternate
splicing. Many mutations at donor splice site positions –1 and –2
have now been described in COL7A1 (Gardella et al, 1996; Kon
et al, 1998; Terracina et al, 1998) and work at the mRNA level
has demonstrated that mutations at these positions cause the
synthesis of several alternate transcripts. Some of these transcripts
are normal, some have the entire exon spliced out, and some use
cryptic donor sites and contain only a part of the exon. These
mutations may therefore lead to a milder phenotype because of the
presence of the normal transcript (Cserhalmi-Friedman et al, 1997;
Terracina et al, 1998). These findings have been supported in many
other genetic disorders such as cholesteryl ester storage disease
(Redonnet-Vernhet et al, 1998; Ries et al, 1998), Fabry disease
(Chen CH et al, 1998), long QT syndrome (Kanters et al, 1998),
and cerebrotendinous xanthomatosis (Chen W et al, 1998).
We have also detected 22 novel deletions or insertions including
the largest characterized within the COL7A1 gene to date
(7288del29). The 15 novel missense mutations detected in this
study consist of 13 glycine substitutions and two arginine substitu-
tions situated within the collagenous domain of type VII collagen.
Of the 65 missense mutations published (Table IV), 27 (42%) lie
between exons 72 and 75 around the hinge region that interrupts
the gly X-Y repeats of the collagenous domain. These data therefore
indicate the importance of this hinge region to the function of
type VII collagen in forming anchoring fibrils.
In summary, we have developed two new mutation detection
techniques for screening the type VII collagen gene, COL7A1, which
are easier, less labor intensive, and cheaper than previously used
methods. It is recommended that when skin is available for RNA
extraction, the PTT procedure be used as a rapid screen for all
recessive DEB patients; however, if only DNA is available or when
screening dominant DEB patients, then the fl-CCM procedure
should be used. If both RNA and DNA are available then a combina-
tion of both PTT and fl-CCM would enable both a rapid and very
sensitive screening of COL7A1 to be conducted. A combination of
strategies has already proved successful in screening for mutations in
the plectin gene using CSGE and PTT (Takizawa et al, 1999). We
would recommend fl-CCM as a preferred option to CSGE because
in our hands it is more sensitive, semiautomated, and allows for a
higher throughput of patient samples.
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